Key points are not available for this paper at this time.
Advances in highly active antiretroviral therapy (HAART) options for people living with HIV/AIDS have resulted in decreased morbidity and mortality. To some extent, the role of disease progression in eroding quality of life (QOL) erosion in the pre-HAART age is now supplanted by drug toxicities, one of the Achilles' heels of HAART. This article reviews research findings on treatment and QOL outcomes a decade into the HAART era.
Burgoyne et al. (2008) studied this question.